All stock lists
Unlock the score
Precision Biosciences Inc (NASDAQ:DTIL)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
6.41-0.23 (-3.46%)
Market cap
$177M
Insider Score
Health Score
Analyst consensus
Listed since
Mar 28, 2019
Website
Insider Score
/ 100
DTIL Insider Score
PRECISION BIOSCIENCES INC has a live Insider Score.
Scored on 3 qualifying trades from 3 insiders in the last 90 days.
Financial Health Score
Weak
From DTIL’s reported statements · Q2 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $45.1M
- Net income
- -$52.7M
- Net margin
- -117.0%
Leverage14 / 20
A manageable debt load.
- Total debt
- $28.1M
- Cash
- $86.1M
- Debt / equity
- 0.62
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $91.5M
- Current liabilities
- $7.1M
- Current ratio
- 12.82
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$51.9M
- Free cash flow
- -$52.0M
- FCF margin
- -115.3%
Dilution & runway0 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 25.9M
- Share growth (1y)
- 134.1%
- Cash runway
- 20 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
DTIL Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 0.00 | 10.84 M | 34.20 M | 13.00 K | 18.00 K | 29.00 K |
| Revenue Growth (YoY) | -100.00 % | 37272.41 % | 5261.13 % | -97.74 % | -99.96 % | -99.84 % |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 10.84 M | 34.20 M | 13.00 K | 18.00 K | 29.00 K |
| SG&A Expense | 6.77 M | 6.80 M | 7.23 M | 7.33 M | 9.13 M | 8.55 M |
| R&D Expense | 12.39 M | 13.11 M | 14.46 M | 13.35 M | 12.77 M | 13.59 M |
| Operating Expenses | 19.16 M | 19.91 M | 21.70 M | 20.68 M | 21.89 M | 22.14 M |
| Operating Income | -19.16 M | -9.07 M | 12.51 M | -20.67 M | -21.88 M | -22.11 M |
| Pretax Income | -32.65 M | -18.44 M | 19.25 M | -21.77 M | -23.52 M | -20.57 M |
| Tax Provision | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -32.65 M | -18.44 M | 20.13 M | -21.77 M | -23.52 M | -20.57 M |
| EPS (Basic) | -1.26 | -0.75 | 1.06 | -1.84 | -2.13 | -2.30 |
| EPS (Diluted) | -1.26 | -0.75 | 1.05 | -1.84 | -2.13 | -2.29 |
| Shares Outstanding | 25.86 M | 24.63 M | 19.05 M | 11.82 M | 11.05 M | 8.94 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.